Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 2/20 | 0.51 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.51 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 14/20 | 0.46 |
| ▸ | TDP2 | O95551 | 1/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16795680 | 0.90 | LIPG (0.51) | LPLLIPGDGAT1MAOBTDP2 | |
| SCHEMBL16795684 | 0.88 | MAOB (0.53) | LPLLIPGDGAT1MAOBNR4A2 | |
| SCHEMBL21234489 | 0.88 | LPL (0.52) | LPLLIPGDGAT1MAOBTDP2 | |
| SCHEMBL16795621 | 0.88 | DGAT1 (0.57) | LPLLIPGDGAT1MAOBTDP2 | |
| SCHEMBL4659420 | 0.87 | MAOB (0.56) | LPLLIPGDGAT1MAOBNR4A2 | |
| SCHEMBL21221831 | 0.87 | MAOB (0.52) | LPLLIPGDGAT1MAOBTDP2 | |
| SCHEMBL21234488 | 0.87 | LPL (0.54) | LPLLIPGDGAT1MAOBTDP2 | |
| SCHEMBL4659527 | 0.86 | MAOB (0.57) | LPLLIPGDGAT1MAOBNR4A2 | |
| SCHEMBL22290582 | 0.84 | LIPG (0.51) | LPLLIPGDGAT1MAOBTDP2 | |
| SCHEMBL21568905 | 0.83 | LPL (0.59) | LPLLIPGDGAT1MAOBNR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015087094-A1 | NEW ARYLALKENYLPROPARGYLAMINE DERIVATIVES EXHIBITING NEUROPROTECTIVE ACTION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SEMMELWEIS EGYETEM (HU) | 2015-06-18 | — | — | WO | disclosed |